E Kaukel
Overview
Explore the profile of E Kaukel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.
J Clin Oncol
. 2023 Apr;
41(12):2125-2133.
PMID: 37068377
Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase...
2.
Paz-Ares L, Ross H, OBrien M, Riviere A, Gatzemeier U, von Pawel J, et al.
Br J Cancer
. 2008 May;
98(10):1608-13.
PMID: 18475293
Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received...
3.
OBrien M, Anderson H, Kaukel E, OByrne K, Pawlicki M, von Pawel J, et al.
Ann Oncol
. 2004 May;
15(6):906-14.
PMID: 15151947
Background: This open-label, randomised phase III study was designed to further investigate the clinical activity and safety of SRL172 (killed Mycobacterium vaccae suspension) with chemotherapy in the treatment of non-small-cell...
4.
Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.
J Clin Oncol
. 2003 Jul;
21(14):2636-44.
PMID: 12860938
Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase...
5.
Giaccone G, OBrien M, Byrne M, Bard M, Kaukel E, Smit B
Eur J Cancer
. 2003 Mar;
38 Suppl 8:S19-24.
PMID: 12647701
A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural mesothelioma has been completed. The objectives were to evaluate the activity and tolerability...
6.
Bakhshandeh A, Bruns I, Traynor A, Robins H, Eberhardt K, Demedts A, et al.
Lung Cancer
. 2003 Mar;
39(3):339-45.
PMID: 12609573
We performed a phase II study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2...
7.
Gatzemeier U, Kleisbauer J, Drings P, Kaukel E, Samaras N, Melo M, et al.
Am J Clin Oncol
. 2000 Aug;
23(4):393-400.
PMID: 10955871
This phase III study was conducted to evaluate the usefulness of lenograstim as support for ACE (doxorubicin, cyclophosphamide, and etoposide) chemotherapy in previously untreated patients with small-cell lung cancer. Patients...
8.
Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U
Pneumologie
. 1998 Dec;
52(10):570-3.
PMID: 9847635
In the palliative treatment of advanced SCLC and NSCLC there is a big need for effective and well tolerable drugs. Bendamustin is an alcylatic agent which had shown activity in...
9.
Gatzemeier U, Jagos U, Kaukel E, Koschel G, von Pawel J
Semin Oncol
. 1997 Aug;
24(4 Suppl 12):S12-149-S12-152.
PMID: 9331141
Carboplatin/etoposide is an active regimen in the treatment of small cell lung cancer. This phase II trial evaluated whether adding paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this two-drug...
10.
Mezger J, Calavrezos A, Drings P, Gatzemeier U, Kaukel E, Konietzko N, et al.
Lung
. 1994 Jan;
172(3):183-4.
PMID: 8201832
No abstract available.